{"ticker": {"uuid": "1eefc959-30da-4121-8b09-97dc02a596df", "symbol": "601607", "name": "Shanghai Pharmaceuticals Holding Co., Ltd", "exchange": "SHH", "country": "CN", "sector": "Healthcare", "industry": "Medical Distribution"}, "articles": [{"title": "Plans to\u6302\u724c\u51fa\u8ba9 41% equity interest in Shangyao Yiyao Pharmaceutical (Shanghai) Co., Ltd.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSVI4aVFBNm1XaHNkd2lKUWprVnhvY3VuWVBWYl9SRXZ3QVFqajVwU1BLa2V6OElHb2NOWEo5QkstRDVPUGZsVjBoTTJwaGx0aktJZElSb0hYR2NQTzEwNHhWZDZQMEN6b1JuV3JGVTVHTDN3X2JBejVKVHBrQjM1SGxOdzRwdjRVN2JEemtnOHRZYV9YLVYxa1NmRjhrSlh2aG9EMEd4WmVpQQ?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-18T03:40:00+00:00", "published_display": "18 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shanghai Pharmaceuticals (601607.SH): Plans to invest RMB 300 million in the establishment of Shanghai Shangshi Biopharmaceutical Industry Private Equity Fund Partnership Enterprise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPU2ZkTTZxXzZ4M3BtN1ZRMDNXTHcxQV9qOUxFeENhdF9jZ0xFZTQtUE1YRlJEV1YzS3MxSFg4blFEVDZkMkptcmFDbFFUb280eEVtMFZ3b3FLUFFmel9jc3R4X3RORlV0SndPZER5TkVaVVczOXNKSGZJUjZKMU5yQkJSeURPTVFSaWFiRVNqQlIwSVJRWXI1b1dvR3ZRdVJZOXpUS2taNEFYMWc?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-17T12:49:30+00:00", "published_display": "17 Jul 2026 12:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Largest Shareholders Are Private Companies With 39% Ownership, Individual Investors Own 26%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPTnhvbjRLZE5FZGFkZXF5a0dYYmVyWGRfZjhPMnIwemE5amM4ZjhIWC1rX2JPMlVteF9nbjdoYjZmckxFaWNPRTRkZ3A4cjNsdzJwY3lVSjhEOHZ6R1ZWRzlCRmxDZmZKZkgtNmd0YXZfbFF4RExEU3p2MS11RnMzZnJFbEMySlZhY1JjVVpMSEpON2tyYzVjazVrTnpJLU5saEZVQlFIZlZqTlFDdnFPUlMySEI0cjQ?oc=5", "source_name": "Moomoo", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of Shanghai Pharmaceuticals Holding Co. Ltd. Class A (SSE:601607)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9uOHVkUThUUl81eTBybEtPQkpQQUh0bHRIVHdJRGQ1V21Nb1BfczlrVS1vT1VlWlFGcTA5Y0ZkWUY1VE11R09nTnZjYUZqU3llME01LVkwVXNvekdhTzlkSTRlT0dsb1Z0cEE?oc=5", "source_name": "TradingView", "published_at": "2019-01-01T02:37:54+00:00", "published_display": "01 Jan 2019 02:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Plans to\u6302\u724c\u51fa\u8ba9 41% equity interest in Shangyao Yiyao Pharmaceutical (Shanghai) Co., Ltd.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSVI4aVFBNm1XaHNkd2lKUWprVnhvY3VuWVBWYl9SRXZ3QVFqajVwU1BLa2V6OElHb2NOWEo5QkstRDVPUGZsVjBoTTJwaGx0aktJZElSb0hYR2NQTzEwNHhWZDZQMEN6b1JuV3JGVTVHTDN3X2JBejVKVHBrQjM1SGxOdzRwdjRVN2JEemtnOHRZYV9YLVYxa1NmRjhrSlh2aG9EMEd4WmVpQQ?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-18T03:40:00+00:00", "published_display": "18 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shanghai Pharmaceuticals (601607.SH): Plans to invest RMB 300 million in the establishment of Shanghai Shangshi Biopharmaceutical Industry Private Equity Fund Partnership Enterprise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPU2ZkTTZxXzZ4M3BtN1ZRMDNXTHcxQV9qOUxFeENhdF9jZ0xFZTQtUE1YRlJEV1YzS3MxSFg4blFEVDZkMkptcmFDbFFUb280eEVtMFZ3b3FLUFFmel9jc3R4X3RORlV0SndPZER5TkVaVVczOXNKSGZJUjZKMU5yQkJSeURPTVFSaWFiRVNqQlIwSVJRWXI1b1dvR3ZRdVJZOXpUS2taNEFYMWc?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-17T12:49:30+00:00", "published_display": "17 Jul 2026 12:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Largest Shareholders Are Private Companies With 39% Ownership, Individual Investors Own 26%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPTnhvbjRLZE5FZGFkZXF5a0dYYmVyWGRfZjhPMnIwemE5amM4ZjhIWC1rX2JPMlVteF9nbjdoYjZmckxFaWNPRTRkZ3A4cjNsdzJwY3lVSjhEOHZ6R1ZWRzlCRmxDZmZKZkgtNmd0YXZfbFF4RExEU3p2MS11RnMzZnJFbEMySlZhY1JjVVpMSEpON2tyYzVjazVrTnpJLU5saEZVQlFIZlZqTlFDdnFPUlMySEI0cjQ?oc=5", "source_name": "Moomoo", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of Shanghai Pharmaceuticals Holding Co. Ltd. Class A (SSE:601607)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9uOHVkUThUUl81eTBybEtPQkpQQUh0bHRIVHdJRGQ1V21Nb1BfczlrVS1vT1VlWlFGcTA5Y0ZkWUY1VE11R09nTnZjYUZqU3llME01LVkwVXNvekdhTzlkSTRlT0dsb1Z0cEE?oc=5", "source_name": "TradingView", "published_at": "2019-01-01T02:37:54+00:00", "published_display": "01 Jan 2019 02:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 61, "total_relevant": 4, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 4, "score": 50, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 71, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 16.61, "latest_week": "2026-07-17", "one_week_move": 5.1, "four_week_move": 6.6, "twelve_week_move": -1.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.479477, "market_dynamics_buy_signal": false, "relative_strength": -0.403284, "fair_value_gap": -7.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.851, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.1% over one week, +6.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "\u5bcc\u9014\u725b\u725b", "count": 2}, {"label": "Moomoo", "count": 1}, {"label": "TradingView", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "71/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.1% over one week, +6.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Plans to\u6302\u724c\u51fa\u8ba9 41% equity interest in Shangyao Yiyao Pharmaceutical (Shanghai) Co., Ltd."}], "updated_at": "2026-07-21T15:35:00.942706+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}